Serplulimab Combined Therapy for Metastatic Pancreatic Adenocarcinoma
Practical Solutions and Value
Patients with metastatic pancreatic adenocarcinoma face a poor prognosis despite chemotherapy. This study aims to evaluate the effectiveness and safety of a combined treatment approach using PD-1 blockade, gemcitabine plus nab-paclitaxel chemotherapy, and stereotactic body radiotherapy (SBRT).
This is a phase II clinical trial involving 43 patients, where the primary endpoint is the 6-month progression-free survival rate. Secondary endpoints include overall survival, overall response rate, and safety measures. The study also aims to investigate biomarkers in patients diagnosed with metastatic pancreatic adenocarcinoma.
The study has been approved by the Ethics Committee on Biomedical Research, West China Hospital of Sichuan University, and the results will be presented at international conferences and published in a peer-reviewed journal.
Value in Clinical Practice
Clinical trials play a crucial role in developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates clinical protocols and research, making it easier for clinicians to access essential knowledge. Additionally, our mobile apps support scheduling, treatment monitoring, and telemedicine, streamlining operations and expanding digital services to improve patient care and outcomes.
By leveraging AI, clinics can enhance workflows, reduce paper routines, and ultimately improve patient outcomes. Learn more about our solutions at aidevmd.com.
